Literature DB >> 7696855

Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions.

H Inohara1, A Raz.   

Abstract

Citrus pectin (CP) and pH-modified citrus pectin (MCP) are highly branched and non-branched complex polysaccharides, respectively, rich in galactoside residues, capable of combining with the carbohydrate-binding domain of galectin-3. We reported previously that intravenous injection of B16-F1 murine melanoma cells with CP or MCP into syngeneic mice resulted in a significant increase or decrease of lung colonization, respectively (Platt D, Raz A (1992) J Natl Cancer Inst 84:438-42). Here we studied the effects of these polysaccharides on cell-cell and cell-matrix interactions mediated by carbohydrate-recognition. MCP, but not CP, inhibited B16-F1 melanoma cells adhesion to laminin and asialofetuin-induced homotypic aggregation. Both polysaccharides inhibited anchorage-independent growth of B16-F1 cells in semisolid medium, i.e. agarose. These results indicate that carbohydrate-recognition by cell surface galectin-3 may be involved in cell-extracellular matrix interaction and play a role in anchorage-independent growth as well as the in vivo embolization of tumour cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7696855     DOI: 10.1007/bf00731303

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  31 in total

1.  Dichotomy in the laminin-binding properties of soluble and membrane-bound human galactoside-binding protein.

Authors:  J Ochieng; M Gerold; A Raz
Journal:  Biochem Biophys Res Commun       Date:  1992-08-14       Impact factor: 3.575

2.  Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis.

Authors:  A Raz; D G Zhu; V Hogan; N Shah; T Raz; R Karkash; G Pazerini; P Carmi
Journal:  Int J Cancer       Date:  1990-11-15       Impact factor: 7.396

3.  Identification of the metastasis-associated, galactoside-binding lectin as a chimeric gene product with homology to an IgE-binding protein.

Authors:  A Raz; G Pazerini; P Carmi
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

Review 4.  Lectins as cell recognition molecules.

Authors:  N Sharon; H Lis
Journal:  Science       Date:  1989-10-13       Impact factor: 47.728

Review 5.  Endogenous lectins as mediators of tumor cell adhesion.

Authors:  R Lotan; A Raz
Journal:  J Cell Biochem       Date:  1988-05       Impact factor: 4.429

6.  Differential expression of endogenous lectins on the surface of nontumorigenic, tumorigenic, and metastatic cells.

Authors:  A Raz; L Meromsky; R Lotan
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

Review 7.  Use of transfection to analyze genetic information and malignant transformation.

Authors:  R A Weinberg
Journal:  Biochim Biophys Acta       Date:  1981-08-31

Review 8.  Soluble lectins: a new class of extracellular proteins.

Authors:  S H Barondes
Journal:  Science       Date:  1984-03-23       Impact factor: 47.728

9.  Melanoma cell adhesion to basement membrane mediated by integrin-related complexes.

Authors:  R H Kramer; K A McDonald; E Crowley; D M Ramos; C H Damsky
Journal:  Cancer Res       Date:  1989-01-15       Impact factor: 12.701

10.  Asparagine-linked oligosaccharides containing poly-N-acetyllactosamine chains are preferentially bound by immobilized calf heart agglutinin.

Authors:  R K Merkle; R D Cummings
Journal:  J Biol Chem       Date:  1988-11-05       Impact factor: 5.157

View more
  40 in total

1.  Galectin-3 induces endothelial cell morphogenesis and angiogenesis.

Authors:  P Nangia-Makker; Y Honjo; R Sarvis; S Akahani; V Hogan; K J Pienta; A Raz
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs.

Authors:  Olga V Glinskii; Virginia H Huxley; Gennadi V Glinsky; Kenneth J Pienta; Avraham Raz; Vladislav V Glinsky
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

3.  The inhibitory effects of a rhamnogalacturonan I (RG-I) domain from ginseng pectin on galectin-3 and its structure-activity relationship.

Authors:  Xiaoge Gao; Yuan Zhi; Lin Sun; Xiaoxia Peng; Tao Zhang; Huiting Xue; Guihua Tai; Yifa Zhou
Journal:  J Biol Chem       Date:  2013-10-07       Impact factor: 5.157

Review 4.  Nuclear transport of galectin-3 and its therapeutic implications.

Authors:  Tatsuyoshi Funasaka; Avraham Raz; Pratima Nangia-Makker
Journal:  Semin Cancer Biol       Date:  2014-03-19       Impact factor: 15.707

Review 5.  Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting.

Authors:  James V Michael; Lawrence E Goldfinger
Journal:  Semin Cancer Biol       Date:  2017-12-02       Impact factor: 15.707

Review 6.  Why anti-Bcl-2 clinical trials fail: a solution.

Authors:  Y Harazono; K Nakajima; A Raz
Journal:  Cancer Metastasis Rev       Date:  2014-03       Impact factor: 9.264

7.  [Galectin expression in urological cancer. Diagnostic, prognostic and therapeutic potential].

Authors:  S Waalkes; A S Merseburger; A Simon; J Serth; M A Kuczyk
Journal:  Urologe A       Date:  2010-03       Impact factor: 0.639

8.  Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions.

Authors:  Malathy P V Shekhar; Pratima Nangia-Makker; Larry Tait; Fred Miller; Avraham Raz
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model.

Authors:  Hai-Ying Liu; Zhi-Liang Huang; Guo-Hua Yang; Wei-Qun Lu; Nan-Rong Yu
Journal:  World J Gastroenterol       Date:  2008-12-28       Impact factor: 5.742

Review 10.  Galectin-3 and metastasis.

Authors:  Yukinori Takenaka; Tomoharu Fukumori; Avraham Raz
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.